Tag Archives: RESI

RESI Boston 2017: Agenda Announced

6 Jul

By Lucy Parkinson, Director of Research, LSN

On September 26th, RESI will come home to Boston. In our year on the road, LSN has expanded our reach into new areas, and it’s time to lead the RESI Tribe back home – including many new investors and exciting emerging technology companies that we’ve met on our travels.

LSN would now like to announce the agenda for RESI Boston. The event will include 24 investor panels and entrepreneur workshops, including new panel content from our sponsors at the NIH, and a new session dedicated to Payers & Providers who invest in early stage technologies. RESI Boston will also feature an Asia-North America healthcare investment track. Check out the full content below. If you want to take part, don’t miss out on your opportunity to catch the early bird price by registering now.

LSN Announces Premier Partnering Plus For RESI Conference Series

6 Jul

By Natasha Eldridge, RESI Conference Manager, LSN

natasha-wp-new

Life Science Nation is announcing “Premier Partnering Plus” as a new service to augment the RESI Conference series. Premier Partnering Plus provides deep insight into the investors and strategic partners that regularly attend RESI conferences in search of assets to partner with and invest in. LSN, the creator of RESI, sells a world class investor and strategic partner database to scientist-entrepreneurs and fundraising CEOs, and now RESI attendees can get partial access to that data and review the deep profiles that come with this one-of-a-kind database as part of the RESI partnering experience. This will make for better alignment for both sides of the meeting table as the sell side attendees will now have detailed investment and deal mandate information to help dial in who they need to meet with based on fit. This will include specifics on the sectors, subsectors, and indication interest, company and management team requirements, typical allocation size and the contact information and best way to reach out to an investor. Premier Partnering Plus users will not be just limited to the RESI Partnering message system to reach out to investors – now they will have the capability to reach out through the partnering system or with the direct contact info provided with the Premier Partnering Plus profile.

These investment mandates will be imported from the LSN Investor Platform that has more than 5,000 investors listed. This information is gathered by the LSN Research team, based on one-on-one conversations with the investors and updates gathered every 6 months. The RESI Premier Partnering is available for additional per company fee. This a first for integrating a world class investor & strategic data platform with a partnering application, and will make attendees who use the service much more selective, efficient and successful in their partnering activities.

RESI Testimonials – Hear from the Folks Who Attended

29 Jun

By Michael Quigley, VP of Market Research, LSN

mike-2RESI San Diego was another successful event for fundraising life science companies, investors and strategic partners. With a great deal of praise coming from those on both sides of the investment table, you can read the testimonials below to see for yourself what industry executives are saying about RESI.

 

Brian Frenzel, MBA: Membership Committee, Band of Angels; President, CEO and Director Tosk, Inc.

Congratulations on a great RESI meeting in San Diego last week. I have been attending biomedical conferences for longer than I’d like to admit – ABC, ACA, ACOG, ASA, ASCO, BIO, DMD, H&Q, JPM, MnM, PhRMA, and many others, some whose acronyms are slowly being lost to history.

The RESI meeting in San Diego was one of the best organized and most productive that I have ever attended. The event’s sole focus on early stage investments and fundraising along with the partnering system made it very easy to identify companies of interest and schedule meetings. RESI staff were always available to help. The energy level was very high, and I was delighted to see so many new companies, new technologies, and new investors in attendance. Not only did I fill every meeting slot, but extended it into lunch, the reception, the following day, and the following week. I am confident that several companies I met at RESI will yield new business relationships.

My hat’s off to you and the RESI staff that made it possible!

Gregory Stein MD, MBA: President and CEO Curtana Pharmaceuticals

Congratulations on running yet another successful RESI conference! I have attended several over the past 3 years and they just keep getting better. The partnering system makes it easy to identify leads and I always have a packed meeting schedule with potential investors and partners that I could not have otherwise found through the usual channels. While I did not see immediate success, you and I both know this is, in part, a numbers game and persistence pays. It has taken a lot of work, but this past March I closed with one investor group and in July I will close with another group that has committed to invest. From the recent San Diego conference, I have several new high-quality investor leads and partnering opportunities to follow-up on in the coming weeks. Given the enthusiastic response I received to Curtana’s story, I anticipate that we will continue to benefit from the relationships we have made at the RESI conferences.

Yao Ho MBA: Business Development Director LYFE Capital

Attending numerous RESI from a few years back, I can say that the events are getting increasingly better and a must go to event to meet quality companies. Attendees from the investor side has also been increasing in quantity and quality, almost feeling like a 1:1 attendee ratio. The partnering system is intuitive to use and makes identifying promising companies to meet quite easy. From the event I have met many new business relationships that I expect will flourish in not only in the business setting but also as friends. Most importantly the follow-up rate from meetings held at RESI is also quite high, proving to me that the quality and dedication of these companies are certainly a par above. The RESI team has always been helpful in addressing any concerns and helping build new leads. I am certain that we will be attending future RESI events and look forward to seeing RESI flourish. Congrats to the RESI team on making another great event!

RESI San Diego 2017 Innovation Challenge – Winners Announced

22 Jun

By Nono Hu, Director of Marketing, LSN

On June 19, more than 600 healthcare entrepreneurs and investors entered the exhibition hall at the Westin San Diego Gaslamp Quarter. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and healthcare IT sectors. The 30 companies, hand selected by LSN’s scientific and commercial review team, competed directly on merits of innovation and commercial viability. Here, LSN would like to present the top 3 winners who attracted the greatest amount of “RESI Cash”.

First Place: Taithera

Taithera is redefining orthopaedics. Taithera is developing a first-in-class bone targeted drug delivery platform for the treatment of musculoskeletal disorders. The core of Taithera’s revolutionary platform is a nanoparticle that is programmed to deliver therapeutics directly to the site of a bone lesion. This hyper-targeted delivery platform can be used to treat primary and metastatic bone cancers, fractures, osteoporosis, and other bone conditions. Taithera is based in New York City, and was founded by Mo Chen, PhD and Seth Harlem.

Michael Quigley, VP of Market Research, Life Science Nation | Mo Chen, Co-Founder & Chief Science Officer, Taithera | Seth Harlem, Co-Founder & Chief Executive Officer, Taithera

Second Place: Tasso

Tasso is a medical device company that is developing the HemoLink, a user-friendly way to self-collect blood for clinical testing that has the potential to fundamentally change how people interface with healthcare. The HemoLink is a device that enables high-quality blood sample collection with one press of a button. After the blood draw is complete, the tube appended to the device simply twists off and can be used directly within standard lab processes. The HemoLink is enabled by novel microfluidic technologies that enable connectivity (e.g. tube types), simple low-cost manufacturing, and plasma separation onsite. The HemoLink can replace phlebotomy in small clinics and bring blood collection to the home.

Michael Quigley, VP of Market Research, Life Science Nation | Ben Casaavant, VP, Engineering, Tasso

Third Place: ViewsIQ

ViewsIQ is a medical technology company, digitizing patient samples microscopically to disrupt the pathology practice – the last remaining medical imaging field to go digital. ViewsIQ’s Panoptiq system is the first software-based approach to digital imaging that allows seamless integration into a Pathologist’s clinical workflow. With Panoptiq, the cost barrier to digital imaging has been removed, permitting clinicians to offer expert diagnostic care to patients virtually anywhere in the world.

Michael Quigley, VP of Market Research, Life Science Nation | Herman Lo, CEO, ViewsIQ

Thank you to all who competed in the RESI San Diego Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

1:1 Ratio of Entrepreneurs to Investors at Upcoming RESI Event

15 Jun

By Natasha Eldridge, RESI Conference Manager, LSN

natasha-wp-newHow do you get the most out of a day of networking and one-to-one meetings? It’s all about being able to connect with the right partners. At RESI, hundreds of highly innovative early stage companies in drug development, medical devices, diagnostics and healthcare IT come to meet with hundreds of early stage investors focused on those verticals. RESI gathers attendees from not just all over North America, but all over the world. The investors in attendance are very diverse, representing both traditional funding sources like venture capital firms and large pharmas, and also newer sources in early stage investment such as family offices and nonprofit foundations. Via RESI’s uniquely curated Partnering system, attendees can zero in on the most relevant potential investors and ensure that their meetings will have a strong basis in mutual fit. Want to take part?

Register here now

New at RESI San Diego: Genomics Investors in the Spotlight

15 Jun

By Lucy Parkinson, Director of Research, LSN

Genomic innovation cuts across many technology verticals.  The dawn of efficient and inexpensive gene sequencing enabled many breakthrough discoveries in biology by identifying genes that have a role in specific diseases. Patients can now be stratified by genetic subtypes in order to identify the most suitable treatment. Some startups aim to use sequencing to identify future health risks. Meanwhile, sequencing has created massive amounts of genetic data, which could yield many further discoveries with the right curation and analysis.

At RESI, a panel of investors with a focus on genomics will discuss what kind of breakthroughs they are looking to back, and what challenges still remain in the genomics field.

Moderated by Amanda Cashin (Head of Illumina Accelerator), the participants are:

RESI San Diego: Check Out the Program Guide Now

8 Jun

By Nono Hu, Director of Marketing, LSN

With 10 days to go until the first RESI San Diego event, LSN is proud to present the latest RESI program guide. If you want to see the full lineup of sponsors, investor panelists, RESI Innovators and speakers, you’re in the right place. RESI San Diego will bring together hundreds of active investors and early stage startups to begin their BIO week with a dedicated day of partnering, networking, and early stage-focused content. Check out the details below.